Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus

Reichard, Kirk W.; Lorence, Robert M.; Katubig, Burt B.; Peeples, Mark E.; Reyes, Hernán M.

doi:10.1016/s0022-3468(05)80302-1

Cited by 10 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sialoglycoconjugate expression in general is related to the expression of some oncogenes (e.g. ras and myc) [12,13] , which may be a possible link to MuV sensitivity since sialic acid is important in MuV attachment to host cells [14,15] .…”

Section: Discussionmentioning

confidence: 99%

Selective Cytolysis of Tumor Cells by Mumps Virus S<sub>79</sub>

et al. 2005

View full text Add to dashboard Cite

We studied the sensitivity of several human cancer cell strains (HeLa, HT1080, SPC-A1, and ACHN) and normal cell strains (MRC-5 and Wish) to mumps virus (MuV) S₇₉, a live attenuated vaccine strain. These cells exhibited a differential sensitivity to infection with MuV, and the susceptible sequences were ACHN > HeLa > HT1080 > SPC-A1 > Wish > MRC-5. In experiments in vivo, nude mice with HT1080 fibrosarcoma xenografts were randomly divided into three groups for intratumoral treatment with MuVS₇₉, UV-inactivated MuVS₇₉, and PBS. At 10⁷ PFU, live MuVS₇₉ injection caused in 7 of 9 mice complete regression by day 15 while rapid tumor growth occurred in all 9 mice treated with PBS. Rapid tumor progression also occurred in all 8 mice treated with UV-inactivated virus; however, tumor growth was delayed in the logarithmic phase relative to the PBS-treated tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Selective Cytolysis of Tumor Cells by Mumps Virus S<sub>79</sub>

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Promising results were noted in preclinical models of leukemia, lymphoma, melanoma, neuroblastoma, fibrosarcoma, rat pheochromocytoma, colon carcinoma, lung carcinoma, prostate carcinoma, breast carcinoma, gastric carcinoma, mesothelioma, and head and neck carcinoma [7,9,12,13,26,27,31,34–36,56,59,68,70,77,92,107,108,122–128]. Clinical studies that followed consisted of NDV-based tumor vaccines and direct administration of naturally-occurring NDV to patients with advanced cancers and in post-operative setting.…”

Section: Clinical Trials With Oncolytic Ndvmentioning

confidence: 99%

Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions

2012

View full text Add to dashboard Cite

Summary Newcastle Disease Virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research leading to the elucidation of the mechanisms of NDV-mediated oncolysis as well as the development of novel oncolytic agents through the use of genetic engineering. Clinical trials utilizing NDV strains and NDV-based autologous tumor cell vaccines will expand our knowledge of these novel anti-cancer strategies and will ultimately result in the successful use of the virus in the clinical setting.

show abstract

“…While Ras is the main factor determining NDV tropism, mutations in the IFN signalling pathway also confer sensitivity to NDV. Live attenuated strains of NDV have shown efficacy in mouse models of fibroblastoma (Lorence et al, 1994a), neuroblastoma (Lorence et al, 1994b;Reichard et al, 1993), colon (Schulze et al, 2009), prostate (Phuangsab et al, 2001), melanoma (Zamarin et al, 2009), large cell lung (Phuangsab et al, 2001) and breast carcinoma (Zhao et al, 2008;Janke et al, 2007). Moreover, live attenuated NDV strains MTH-68/H and PV701 are currently in clinical trials for high-grade gliomas (HGG) and advanced solid cancer, respectively (Csatary et al, 2004;Pecora et al, 2002).…”

Section: Newcastle Disease Virusmentioning

confidence: 99%